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Abstract 
Breast cancer incidence and mortality rates are increasing despite our current knowledge on the disease. 95% of 
breast cancer cases correspond to sporadic forms of the disease and are believed to involve an interaction 
between environmental and genetic determinants. The microRNA 17-92 cluster host gene (MIR17HG) has been 
shown to regulate expression of genes involved in breast cancer development and progression. Study of single 
nucleotide polymorphisms (SNPs) located in this cluster gene could help provide a further understanding of its 
role in breast cancer. Therefore, this study investigated 6 SNPs in the MIR17HG using two independent 
Australian Caucasian case-control populations (GRC-BC and GU-CCQ BB populations) to determine 
association to breast cancer susceptibility. Genotyping was undertaken using chip-based matrix assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS). We found significant association 
between rs4824505 and breast cancer at the allelic level in both study cohorts (GRC-BC p = 0.01 and GU-CCQ 
BB p = 0.03). Furthermore haplotypic analysis of results from our combined population determined a significant 
association between rs4824505/rs7336610 and breast cancer susceptibility (p = 5x10-4).  Our study is the first to 
show that the A allele of rs4824505 and the AC haplotype of rs4824505/rs7336610 are associated with risk of 
breast cancer development. However, definitive validation of this finding requires larger cohorts or populations 
in different ethnical backgrounds. Finally, functional studies of these SNPs could provide a deeper 
understanding of the role that MIR17HG plays in the pathophysiology of breast cancer. 
Keywords: association analysis / breast cancer / haplotype / microRNA / single nucleotide polymorphisms 
(SNP) 
Introduction 
 In 2012, 14.09 million people in the world were newly diagnosed with cancer and about 21% of them 
corresponded to breast cancer (1 676 633 cases in total) according to the International Agency for Research on 
Cancer (IARC). It is the most common type of cancer in women worldwide and is estimated to be developed by 
one in eight women living to the age of 90. Breast cancer is also the fifth cause of cancer-related deaths in the 
world (6.4%) and accounted for 197 528 of all cancer related deaths in developed countries. It has become a 
cause for concern since both incidence and mortality rates have increased by more than 20% and 14% 
respectively from figures reported in 2008[1-3]. Sporadic forms of breast cancer account for about 95% of all 
cases and they are most likely the result of interaction between genetic and environmental factors [4-6, 3]. 
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MicroRNAs (miRNAs) are small non-coding single stranded RNA molecules of about 21 to 25 nucleotides in 
length involved in gene regulation at the translational level. They account to about 1% of the human genome 
and are very likely to be important in cancer biology due to their role in regulating important cellular processes 
like cell growth, differentiation and cell survival [7-9, 3, 10]. miRNAs are usually generated following the 
canonical pathway where they are transcribed from long microRNA primary transcripts (pri-miRNAs) about 
1kb in size that contain up to six miRNA precursors (pre-miRNA). Pre-miRNAs are stem-loop molecules of 
about 55 to 70 nucleotides in length and they are produced when pri-miRNA are cleaved by the complex Drosha 
– DCGR8 (DiGeorge syndrome critical region gene 8, also known as pasha) within the cellular nucleus. Pre-
miRNAs are then transported to the cytoplasm by XPO5 (exportin5) and the nuclear protein Ran-GTP. In the 
cytoplasm pre-miRNAs are processed by DICER1, a ribonuclease type III enzyme, and double-stranded RNA 
binding proteins (RBP) TARBP2 and/or PKRA producing a duplex molecule that contains both the single-
stranded mature miRNA sequence and its complementary strand named miRNA*. The miRNA:miRNA* 
molecule is loaded into the RNA-induced silencing complex (RISC), where the mature miRNA sequence is 
merged into the Argonaute/EIFC2C (Ago) proteins and the miRNA* is released and degraded. Ago proteins 
bound to mature miRNA mediate target messenger RNA (mRNA) recognition and interaction between these 
three components results in gene regulation. The mRNA target is recognised by pairing of the miRNA seed 
region (nucleotides 2 to 8) located in the 5’-end of the miRNA and the complementary sequence mainly located 
in the 3’-UTR region of the mRNA[11-14].  Each miRNA may bind to up to 200 gene targets and each gene 
could have multiple binding sites for different miRNAs [15, 16].  Location of promoter regions of microRNA 
genes, mechanisms that regulate their biogenesis and molecular mediators of their functional effects within cells 
and tissues are still being studied and remain unclear for most miRNAs identified  to date [17, 18]. 
Around 52% of all miRNA genes are located in different non-random positions within the genome, generally in 
regions of chromosomal instability or cancer-associated regions [19]. Changes in miRNA synthesis, expression 
and effect on target genes in relation to cancer could occur through many different mechanisms and some of 
them include: point mutations in miRNA genes, mRNA sequences and surrounding regions, epigenetic changes 
such as mRNA gene methylation, loss or mutation in the promoter regions for specific miRNA clusters and/or 
alterations in pathway related RBP [8, 17].  
Approximately one-third of all miRNAs form genomic clusters, about 113 in total, which may measure up to 51 
kb in length, and they are usually transcribed as a single polycistronic transcript [10, 8]. One such cluster is the 
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microRNA 17-92 cluster host gene (MIR17HG) located on chromosome 13q31.3 in the third intron of the 
c13orf25 gene. It was initially identified in relation to B cell lymphoma both in cell lines and tissue sample from 
patients by Ota et al in 2004[20].  The MIR17HG cluster transcript is about 800bp in length and contains six 
miRNAs: MIR17, MIR18A, MIR19A, MIR20A, MIR19B1 and MIR92A1, which belong to 4 seed families 
(miRNA 17, miRNA 18, miRNA 19 and miRNA 92). Based on their seed sequences, two related paralogues of 
this cluster have also been identified in the human genome: microRNA 106b 25 cluster located on chromosome 
7 (7q22.1) in the 13th intron of gene MCM7 and microRNA 106a-363 cluster located on chromosome X 
(Xq26.2) [21].  
The MIR17HG was named oncomiR-1 by He et al who found it to promote oncogenesis in B-cell lymphoma 
using a murine model [22]. Further studies have confirmed roles both in cell proliferation and cell death, a 
feature that seems to be dependent on the cell types and tissues in which it is found. Research has shown that the 
MIR17HG inhibits tumour growth by targeting important cell cycle regulator genes including E2F1, MYC, RB1 
and CCND1. In 2005, O’Donnell et al observed that MIR17HG down-regulated expression of both E2F1 and 
MYC genes using Burkitt lymphoma cells (P493-6) as a model [23]. On the other hand, later studies have 
shown this cluster gene region seems to have an oncogenic effect in other types of tumour. Experimental models 
of human B-cell lymphomas overexpressing MIR17HG showed evasion of apoptosis due to enhanced activity of 
MYC. Moreover, studies of small-cell lung carcinomas showed negative regulation of the pro-apoptotic gene 
BCL2L11 resulting from overexpression of MIR17HG [24]. This finding may suggest that fine regulation of 
MIR17HG expression is important. Research studies indicate that specific processing of miRNAs included in 
this cluster might be the result of largely unknown intricate regulatory mechanisms. There are 34 transcription 
factors that regulate MIR17HG transcription identified to date and they include MYC, MYCN, MXI, E2F3 and 
TP53 amongst others, that are specific to different cell types and biological contexts [25, 26].  
In relation to breast malignancies, a number of studies on the effects of MIR17HG in breast cancer cell lines 
have also been published. In 2006 MIR17 5p, one of the miRNAs included in the cluster, was shown to inhibit 
oestrogen receptor α (ESR1) co-activator NCOA3 in different breast cancer cell lines [27]. Following this 
finding, Yu et al demonstrated a tumour suppressor role for MIR17HG inducing cell cycle arrest and decreasing 
cell proliferation by directly inhibiting CCND1 in the MCF-7 breast cancer cell line in 2008[28]. Similarly in a 
later study, Leivonen et al showed that MIR17HG reduced cell growth and progression of cell cycle in breast 
cancer cell lines MCF-7 and BT-474 using two mechanisms: translational repression of ESR1 and/or 
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downregulation of ESR1 responding genes. Additionally, they were able to confirm their in-vitro findings 
through expression studies on breast cancer tumour samples showing significant association between high 
expression levels of MIR18a and ESR1-negative breast cancer tumours[29].  
According to the evidence previously presented, the MIR17HG seems to play an important role in development 
of different carcinomas including breast cancer.  However, there is a lack of knowledge on the molecular 
mechanisms leading to altered expression or regulation of this particular cluster as well as each of the mature 
miRNAs included in it. Genetic variants such as single nucleotide polymorphisms (SNPs) could potentially 
impact biological processes involved in the production or functional effects of the microRNA 17-92 cluster host 
gene and the study of such variants in relation to cancer could provide insight into its aetiological mechanisms.  
In this study, we genotyped 6 SNPs located in the cluster gene region or in close proximity to it. Genotyping of 
these variants was performed using multiplex PCR and Matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) analysis in two independent Australian Caucasian breast cancer cohorts. 
Results from our allele and haplotype association analysis showed statistical significance for two of the selected 
SNPs and the risk of breast cancer in these Caucasian populations.  
Materials and methods 
Study Populations 
Genotyping was carried out in two independent cohorts of females of Caucasian (Northern European) origin: 
The Genomics Research Centre Breast Cancer (GRC-BC) population and a subset of the Griffith University-
Cancer Council Queensland Breast Cancer Biobank (GU-CCQ BB). GRC-BC population was recruited from the 
Gold Coast Hospital, Southport and it included 244 breast cancer patient samples from patients residing in the 
South East Queensland region. Samples from 187 healthy females with no history of personal or familial cancer 
were used as controls and they were also obtained via the Genomics Research Centre Clinic, Southport, with the 
research approved by Griffith University’s Human Ethics Committee (Approval: MSC/07/08/HREC and 
PSY/01/11/HREC) and the Queensland University of Technology Human Research Ethics Committee 
(Approval: 1400000104). Mean age of the test populations was 57.52 years and 57 years, for cases and controls, 
respectively. 
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Replication was performed using 679 samples from the GU-CCQ BB population. Patient samples were 
collected by the Genomics Research Centre in collaboration with the Cancer Council of Queensland as part of a 
5-year population-based longitudinal study of women newly diagnosed with breast cancer. 929 women resident 
in Queensland with a diagnosis of invasive breast cancer confirmed histologically have been recruited by this 
biobank since January 2010. Age range of patient samples included in this study varied from 33 to 80 years, 
with an average age of 60.16. Clinical and demographic information was obtained through the Queensland 
Cancer Registry, Genomics Research Centre General Questionnaire, computer assisted telephone interview 
(CATI) and self-administered questionnaires (SAQ) over two main time points: 4 to 6 months post diagnosis 
and 18 months post diagnosis [approximately 12 months after initial interview]. Additionally, using the 
Queensland Cancer Registry and the National Death Index, the study cohort will be followed-up for five years 
post diagnosis to record cancer recurrence and mortality [30]. 308 ethnicity and sex matched control samples for 
the GU-CCQ BB population were obtained from 2 sources: 107 females with no personal or familial history of 
cancer, recruited from January 2000 through the Genomics Research Centre at the Institute of Health and 
Biomedical Innovation Institute, Queensland University of Technology and also genotyping data obtained from 
201 individuals belonging to the phase 1 European population from the 1000Genomes project [31].     
Genomic DNA sample preparation from whole human blood.  
Genomic DNA was obtained from whole blood samples using a modified salting out method [32, 33]. DNA 
samples were checked for quantity and purity using spectrophotometry measurements using the Thermo 
Scientific NanoDropTM 8000 UV-Vis Spectrophotometer (Thermo Fisher Scientific Inc., Wilmington, DE. 
USA) to determine concentration and 260/280 ratios [34-36]. To guarantee DNA sample quality, those with a 
value below 1.7 for their 260/280 ratio were further purified using an ethanol precipitation protocol [37].  
miRNA SNP selection 
We used the human miRNA disease database (HMDD), developed by Lu et al [38] and updated in January 
2012, to identify microRNAs involved in development and progression of breast cancer. We selected 24 
biological/cellular functions and 8 diseases and/or pathological features related to breast cancer from two 
datasets included in the HMDD: “The whole miRNA-disease association data” and “The miRNA function set 
data”. The microRNA 17-92 cluster host gene (MIR17HG) was found to be present in most of the features on 
each dataset and therefore we conducted a preliminary literature search to determine its role in cancer 
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development and progression and to find SNP genotyping studies for this cluster gene. Following this, we 
searched for previously identified SNPs in the MIR17HG using both the dbSNP database from The National 
Center for Biotechnology Information (NCBI) [39] and 1000 Genomes project browser [31]. MicroRNA SNPs 
(miR-SNPs) that were located inside the pre-miRNA gene were automatically included in a preliminary 
selection and those located outside of the pre-miRNA gene were selected using either one of the following 
criteria: SNPs located within 500bp to the 3’ or 5’ end of the pre-miRNA gene region were automatically 
included in the preliminary selection. Finally, miR-SNPs located at a distance higher than 500bp from either end 
of the pre-miRNA gene were chosen only if they had a minor allele frequency (MAF) higher than 0.05 in 
Caucasian populations. Our preliminary selection identified 13 miR-SNPs in the MIR17HG or located up to 1.6 
kb downstream and two variants (rs72631821 and rs9589207) located inside one of the mature miRNA 
sequences (MIR92A1) (See Table 1).  
Primer design and multiplex PCR genotyping 
We were able to design a multiplex PCR assay to include six miR-SNPs: one of the variants located inside the 
MIR92A1 gene (rs9589207) and five miR-SNPs located throughout the MIR17HG region using the 
MassARRAY® Assay Design Suite v1.0 software (SEQUENOM Inc., San Diego, CA, USA). Two PCR 
primers (forward and reverse) and one iPLEX® (extension) primer were designed for each miR-SNP to achieve 
successful marker and allele identification by mass spectrometry (See Table 2). We verified that masses of 
extension primers differed by at least 30 Da among different SNPs and by 5 Da between alternative alleles of 
the same marker and primers were synthesized by Integrated DNA Technologies (IDT®) Pte. Ltd. (Baulkham 
Hills, NSW 2153, Australia). Multiplex PCR reactions were performed according to the manufacturer’s protocol 
for the iPLEX™ GOLD genotyping application using iPLEX® GOLD reaction kit reagents (SEQUENOM Inc., 
San Diego, CA, USA). Primer extension reactions were carried out using the SEQUENOM linear adjustment 
method as per manufacturer’s iPLEX® GOLD genotyping protocol. All iPLEX® GOLD genotyping reactions 
were performed using Applied Biosystems® MicroAmp® EnduraPlate™ Optical 96-Well Clear Reaction Plates 
with Barcode  (Life Technologies Australia Pty Ltd., Mulgrave, VIC, Australia) and a Applied Biosystems® 
Veriti® 96-Well Thermal Cycler (Life Technologies Australia Pty Ltd., Mulgrave, VIC, Australia).  
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MALDI-TOF MS analysis and data analysis 
We dispensed a total of 12-16 nl of each iPLEX® reaction product onto a SpectroCHIP® II G96 (SEQUENOM 
Inc., San Diego, CA, USA) using SEQUENOM® MassARRAY® Nanodispenser (SEQUENOM Inc., San Diego, 
CA, USA) and SpectroCHIP® analysis was performed by SEQUENOM® MassArray® Analyzer 4 
(SEQUENOM Inc., San Diego, CA, USA). We acquired automated spectra after laser desorption/ionisation 
using the SpectroAcquire software version 4.0 (SEQUENOM Inc., San Diego, CA, USA) and genotype data 
analysis was performed using the MassARRAY® Typer software version 4.0 (SEQUENOM Inc., San Diego, 
CA, USA). 
Statistical Analysis 
We determined genotype and allele frequencies for each miRNA SNP in our case and control populations. 
Hardy-Weinberg equilibrium (HWE)[40, 41] was used to evaluate deviation between observed and ideal Hardy-
Weinberg frequencies. Differences in genotype and allele frequencies between cases and controls were 
evaluated using Chi-square analysis[42] for each independent population to determine association with breast 
cancer. The α for p-values was set at 0.05 to determine statistical significance. Statistical analysis of genotypes 
and alleles was conducted using Plink software version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/) [43]. 
We also calculated odds ratio (OR) and a confidence interval (CI) of 95% to assess disease risk. Finally, we 
merged results from both populations and we performed linkage disequilibrium (LD) and haplotype block 
association analysis on the combined genotyping data using Haploview software version 4.2 (Daly Lab, Broad 
Institute, Cambridge, MA, USA) [44].  
 Results  
Genotypic Analysis 
Table 3 shows the 6 SNPs genotyped in our study provided good coverage of the MIR17HG. They also included 
rs9589207 located inside a mature miRNA sequence (MIR92A1) and rs1888138 located 578 bp downstream of 
the cluster gene.  All SNPs had a MAF greater than 0.05, with the exception of rs9589207 which had a MAF of 
0.02. We proceeded to include all these SNPs in our multiplex PCR, in particular rs9589207 because of their 
genetic location. However, rs9589207 was finally excluded from our association analysis because we were 
unable to find the mutant allele in our initial genotyping of the GRC-BC cohort.  
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Hence genotyping results of the 5 remaining SNPs obtained from both populations are shown in Table 4. All 
control populations were in HWE (p > 0.05) for all tested SNPs and allele and genotype frequencies closely 
matched those found in Hapmap for Caucasian populations. As shown in Table 4, we were able to validate 
significant difference in allele frequencies between cases and controls for rs4284505 in both the GRC-BC and 
GU-CCQ BB populations using chi-square analysis (p = 0.01 and 0.03 respectively). Statistical analysis of allele 
frequencies in cases and controls in the GRC-BC population for rs7336610 showed significance (p = 0.03), but 
we were unable to obtain a similar finding in our independent replication population (p = 0.10) and all the other 
remaining SNPs showed no significant differences between cases and controls in both populations. We observed 
lower frequencies (38.3% and 35.9% for GRC-BC and GU-CCQ cohorts respectively) of the A allele for 
rs4284505 in cases for both independent populations (See Table 4) and we calculated an odds ratio of 0.70 (CI 
95%: 0.52 – 0.93) for GRC-BC population and of 0.79 (CI 95%: 0.65 – 0.97) for GU-CCQ population. These 
results indicate that the presence of the A allele in this loci seems to have a protective effect on susceptibility to 
breast cancer. 
Finally, chi square analysis of genotypes for all selected MIR17HG SNPs between cases and controls showed 
significant differences for rs4284505 and rs7336610 (p = 0.01 for both SNPs) in the GRC-BC population. 
Interestingly, we were only able to obtain statistical significance in the analysis at the genotype level only for 
rs7336610 in our replication cohort (p = 0.04).  
Haplotypic Analysis 
Following this, we combined genotyping results from both GRC-BC and GU-CCQ populations to conduct 
linkage disequilibrium (LD) and haplotype block association analysis. As shown in Figure 1, two of our selected 
SNPs (rs4284505 and rs7336610) were part of a 3kb LD block (Block 1) with a D’ score of 0.98. Table 5 shows 
frequencies for the different haplotypes in block 1 found in cases and controls, as well as results of haplotype 
association analysis to breast cancer using chi-square analysis.  According to our findings, cases had a lower 
frequency of haplotype AC (36.4%) than controls (43.3%) and statistical analysis proved this haplotype to be 
the most significantly associated with breast cancer (p = 5x10-4). Finally, we calculated an odds ratio for 
haplotype AC of 0.75 with a 95% confidence interval of 0.60 to 0.94 (p = 0.012). Results from our haplotype 
analysis validate our finding for the genotyping analysis at the allele level in rs7336610. These results also 
suggest that for the individuals that carry the AC haplotype, it appears to confer a protective effect on risk of 
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breast cancer in Caucasians reducing the risk of being affected breast cancer to about 25% in comparison to 
other haplotype carriers. 
Discussion 
Breast cancer affects a significant number of women and mortality rates seem to be increasing, despite 
substantial research and our current knowledge of the disease [1, 2]. MicroRNAs are involved in molecular 
pathways leading to cell growth, differentiation and survival and there is enough evidence to show they play a 
significant role in the mechanisms that lead to development and progression of different types of cancer. 
Changes in expression of the microRNA 17-92 cluster host gene, also known as oncomiR-1, were initially 
described in haematopoietic and lung cancers where it was shown to play a role in tumour growth and 
apoptosis[20-24]. Research has also highlighted MIR17HG as an important regulator of genes involved in breast 
cancer pathways. Studies by Hossain et al and Leivonen et al showed it plays a role in regulation of oestrogen 
receptor α (ESR1) in different breast cancer cell lines and tumour tissues through transcriptional downregulation 
of this receptor and genes that interact or co-activate ESR1 [27, 29]. Yu et al found the MIR17HG to have a 
tumour suppressor role through CCND1 inhibition in the MCF-7 cell line [28]. However, we currently lack 
understanding of the specific features that result in altered biogenesis and functional effects of this particular 
miRNA cluster gene in breast malignancies. Therefore the study of single nucleotide polymorphisms located 
inside the MIR17HG using well defined breast cancer cohorts may help to assess whether they have a role on 
the molecular events leading to the development of this disease.  
Selection of 6 miRNA SNPs found 0.6 kb downstream and inside the microRNA 17-92 cluster host gene region 
provided a thorough coverage of the gene and we were able to successfully genotype all of these variants in the 
two available cohorts, even rs9589207 located inside the MIR92A1 transcript. Unfortunately this particular SNP 
was not included in our association analysis because we could not identify the presence of the mutant allele in 
any of our populations.  However two of the five remaining SNPs, rs4248505 located about 1.4 kb downstream 
from MIR17A and rs7336610 found about 1.4 kb upstream from MIR92A1, showed some interesting results on 
our association analysis of breast cancer risk. Moreover, there does not appear to be any previous genotyping 
studies on these variants in relation to breast cancer or other diseases in Caucasian or any other ethnical 
populations. Statistical analysis of our results for rs4284505 showed a significantly higher presence of the A 
allele in healthy individuals for both GRC-BC and GU-CCQ BB populations (p = 0.01 and 0.03 respectively) 
and a reduction in breast cancer risk of up to 30%. We also found higher frequencies for the C allele of 
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rs7336610 in controls in our GRC-BC cohort but failed to establish a similar finding in our replication 
population.  Analysis of the haplotypes present in the LD block rs4284505/rs7336610 showed results consistent 
to our previous finding in the individual SNP analysis, with the presence of the AC haplotype found to have 
significantly higher frequencies in controls (p = 5x10-4) decreasing the risk of developing breast cancer by about 
25%.  
In conclusion via analysis of SNPs from MIR17HG, we were able to identify significant association between 
rs4248505 at the allele level and rs4248505/rs7336610 at the haplotype level with susceptibility to breast 
cancer. To the best of our knowledge this is the first study investigating SNPs in this cluster gene in Caucasian 
breast cancer populations and the first to identify that presence of the AC haplotype significantly affects the risk 
of developing breast cancer. However our findings require further validation in larger populations and/or 
population of different ethnicities, as well as functional studies to determine the role of this haplotype in miRNA 
expression or molecular pathways leading to the development of breast cancer. 
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Table 1 SNPs in the mir-17-92 cluster gene selected for primer design using the MassARRAY® Assay Design Suite v1.0 software (SEQUENOM Inc., San Diego, CA, USA) 
miRNA Locus Location miRNA SNPs in gene region MAF Location 
SNPs near 3' 
end MAF Location 
Downstream 
distance (bp) 
hsa-mir-92a-1 13q31.3 92,003,568 - 92,003,645 
rs72631821  NA 92,003,588 
    
rs9589207 0.0211 92,003,589 
miR-17-92 
Cluster Gene 13q31.3 92,000,074 - 92,006,829 
rs4284505 0.4867 92,001,472 
rs138514639 0.0517 91,998,497 1577 
rs72640333 0.0939 92,004,927 
rs113242099 0.0504 92,005,118 
rs1888138 0.0916 91,999,496 578 rs111371822  0.1484 92,005,134 
rs7336610  0.4524 92,005,137 
rs7318578 0.3594 92,005,469 
rs2351704  0.3539 91,999,716 358 rs17735387 0.0829 92,006,054 
rs1428 0.463 92,006,770 
 
 
 
Table 2 Primer sequences for mir-17-92 SNPs included in genotyping study using multiplex PCR reaction and MALDI-TOF MS 
SNP  Forward primer sequence Reverse primer sequence iPLEX® (Extension) primer sequence 
rs1888138 ACGTTGGATGGTTTATTACTTTACCGGCCC ACGTTGGATGTACTTCTCTGGTTCCGGTTG TGGGTTTCCGAGGTA 
rs7336610 ACGTTGGATGAAAAAGTTCCGGCTGGACAC ACGTTGGATGACAGCGTTTCACCATGTCGG GACTGACCTCAGGTAATCC 
rs9589207 ACGTTGGATGACTCAAACCCCTTTCTACAC ACGTTGGATGGGACAAGTGCAATACCATAC AAGGAACACAGCATTGCAAC 
rs17735387 ACGTTGGATGAGCCTTAACTATTTGGAGGG ACGTTGGATGGCTTTCTTTCCAAATATAGGC GGGGAGAAAGTTGTACATGCAAA 
rs4284505 ACGTTGGATGCTTTGCAGTCTCGGGTGTTC ACGTTGGATGTGATATTGCAACGACGAGCC TGATCCTGCCTTTTTCAGTTCCTT 
rs1428 ACGTTGGATGTCAATATTCTCGTTCTGGAC ACGTTGGATGACAGTTTGGTCTGGCTGTTT GCATTTAATGTTAATAAATAAAATACTG 
 
 
 Table 3 Chromosomal location and allele information for selected miRNA SNPs in the mir-17-92 Cluster gene 
SNP Locus Wild Type allele Mutant allele Chromosomal position MAF 
rs1888138 13q31.3 A T chr13: 91999496 0.0916 
rs4284505 13q31.3 G A chr13: 92001472 0.4867 
rs9589207 13q31.3 G A chr13: 92003589 0.0211 
rs7336610  13q31.3 T C chr13: 92005137 0.4524 
rs17735387 13q31.3 G A chr13: 92006054 0.0829 
rs1428 13q31.3 T G chr13: 92006770 0.4625 
 
 
	  
 
  
Table 4 Allele frequencies of SNPs in the mir-17-92 cluster gene obtained from the GRC-BC and GU-CCQ BB cohorts 
    rs1888138 rs4284505 rs7336610  rs17735387 rs1428 
 
Alleles                                         
Population 
 
A  
(%) 
T  
(%) 
p-
value  
G  
(%) 
A  
(%) 
p-
value  
T  
(%) 
C  
(%) 
p-
value  
G  
(%) 
A  
(%) 
p-
value  
T  
(%) 
G  
(%) 
p-
value  
GRC-BC 
Population 
Control 361  (96.5) 
13  
(3.5) 
0.86  
189  
(53.1) 
167  
(46.9) 
0.01  
185  
(52.6) 
167  
(47.4) 
0.03 
 
360  
(96.3) 
14  
(3.7) 
0.68 
 
182  
(56.2) 
142  
(43.8) 
0.67 
 
Cases 470  (96.3) 
18  
(3.7) 
  
263  
(61.7) 
163  
(38.3) 
  
263  
(60.0) 
175  
(40.0)   
449  
(96.8) 
15  
(3.2)   
278  
(57.7) 
204  
(42.3)   
GU-CCQ BB 
Population 
Control 590  (95.8) 
26  
(4.2) 
0.87  
362  
(58.8) 
254 
(41.2) 
0.03  
346  
(56.2) 
270  
(43.8) 
0.10 
 
590  
(95.8) 
26  
(4.2) 
0.66 
 
383  
(62.8) 
227  
(37.2) 
0.36 
 
Cases 1295  (95.9) 
55  
(4.1) 
 
767  
(64.1) 
429  
(35.9) 
 
712  
(60.1) 
472  
(39.9)  
1287  
(96.2) 
51  
(3.8)  
655  
(60.5) 
427  
(39.5)  
Hapmap (%) 95.9 4.1     57.9 42.1     55.7 44.3     98.2 1.8     65.6 34.4     
 
Table 5 Haplotype block association analysis for selected SNPS in the mir-17-92cluster gene  in combined GRC-BC/GU-CCQ BB population 
	  	   GT	  (%)	   AC	  (%)	   GC	  (%)	  
Control	   269	  (54.3)	   214	  (43.3)	   12	  (2.4)	  
Cases	   544	  (58.9)	   336	  (36.4)	   43	  (4.7)	  
x2	   5.05	   12.21	   6.58	  
p-­‐value	   0.02	   5.0E-­‐04	   0.01	  
Global	  Statistics	   x2	  =	  9.21	  	  	  p-­‐value	  =	  0.01	  
	  

